Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

FDA Grants LUCAS™ 2 Chest Compression System 510(k) Clearance In The United States
Physio-Control Inc., a wholly-owned subsidiary of Medtronic, Inc. (NYSE: MDT), announced today that LUCAS™ 2, the next-generation LUCAS™ Chest Compression System, has been granted 510(k) market clearance by the U.S. Food and Drug Administration (FDA). Developed and manufactured by Jolife AB and distributed exclusively in the United States by Physio-Control, the LUCAS 2 is an automated, battery-powered device that is designed to give consistent, uninterrupted compressions to victims in cardiac arrest.
generic viagra online
The Harley Medical Group Reports On Nipple Surgery Trend
The Harley Medical Group has revealed that the number of nipple correction surgical procedures carried out has risen 30% year-on-year. Mr Riccardo Frati, surgeon at The Harley Medical Group, appeared on GMTV to discuss nipple correction surgery with Lorraine Kelly. He said: "There are nipple surgery options out there and a minority of women seek to change the size or shape of their nipples through reconstructive surgery purely for cosmetic reasons. Another option, nipple elevation, involves the nipple being raised above its existing level to enhance its appearance and make the breast look more pert.
News of the day
Indirect Transmission Can Trigger Influenza Outbreaks In Birds
New data on the persistence of avian influenza viruses in the environment has allowed a team of University of Georgia researchers to create the first model that takes into account both direct and indirect transmission of the viruses among birds. The model, which is detailed in the early online edition of the journal Proceedings of the National Academy of Sciences, has the potential to shed new light on how outbreaks begin in wild bird populations.
Nutrition

Arrayit Corporation Addresses Flu Pandemic

Arrayit Corporation (OTCBB: ARYC), a leading manufacturer of products and services for disease prevention, treatment and cure, announced that its microarray-based diagnostic test, patented under the trade name Variation Identification Platform (VIP), is ready for manufacture and distribution. A breakthrough screening test using VIP will allow clinicians and researchers to test and detect the H1N1 swine flu virus in population wide studies. The World Health Organization (WHO) announced on June 11, that the threat level of the H1N1 swine flu virus is now a global pandemic. This news is ideally timed with Arrayit Corporation"s release of its patented VIP screening test. The Arrayit test will allow researchers and clinicians to detect the presence of the new H1N1 virus in mass numbers of flu patients, and to distinguish this threatening mutated strain from less harmful variants. Arrayit"s first supplies will be sent to the Centers for Disease Control (CDC) in Atlanta to be approved for use in the USA. Shortly thereafter, the H1N1 test kits will be made available for emergency use by licensed clinics, laboratories and other health care organizations worldwide. The VIP screening test is the first of its kind developed for multiple numbers of test subjects, with diagnosis available to patients within hours of testing. Up to 80,000 patients can be screened at a time, making it possible for entire communities and entire countries to quickly identify those infected with the new H1N1 virus. The ability to test and quickly diagnose mass numbers of subjects allows health clinicians the opportunity to gain control of the spread of the virus in a shorter time frame than current individual testing procedures. The VIP test kits will be made available at an affordable cost (estimated at under $50 per individual), making it feasible even for those without health insurance coverage to be screened. Arrayit Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009